Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470964 | 0.92 | THRB (0.57) | THRBLMNACNR1TP53DRD2 | |
| SCHEMBL3472160 | 0.88 | THRB (0.58) | THRBLMNACNR1TP53SMN1; SMN2 | |
| SCHEMBL3472242 | 0.88 | THRB (0.58) | THRBLMNACNR1TP53DRD2 | |
| SCHEMBL3471142 | 0.84 | THRB (0.56) | THRBLMNACNR1 | |
| SCHEMBL3473084 | 0.83 | THRB (0.55) | THRBLMNATP53 | |
| SCHEMBL8211414 | 0.83 | THRB (0.56) | THRBLMNATP53CNR2 | |
| SCHEMBL3471557 | 0.82 | THRB (0.54) | THRBLMNATP53 | |
| SCHEMBL3471601 | 0.82 | THRB (0.59) | THRBLMNASMN1; SMN2DRD2 | |
| SCHEMBL3472582 | 0.82 | THRB (0.60) | THRBLMNADRD2 | |
| SCHEMBL3472728 | 0.81 | THRB (0.58) | THRBLMNACNR1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2008006479-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | F2, TFPI, PLAT | THRB 548/4885LMNA 1715/4885CNR1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.